Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2016

View Archived Issues

Antimitotic compound leiodermatolide reduces pancreatic tumor weights in vivo

IdeS reduces HLA antibodies in kidney transplant candidates

Novel compound E-6887 shows promise for treating lupus

U.S. HHS awards contracts to support development of Zika virus diagnostic tests

Hemispherx Biopharma's NDA for rintatolimod receives approval in Argentina

Orally available peptides from Protagonist Therapeutics show promise for treating IBD

Biotron identifies new compounds in Zika program, signs agreement with NIAID

EMA validates Cempra's MAA for solithromycin

Oncology Venture updates progress of phase I trial of LiPlaCis

Innovative Targeting Solutions signs agreement with Janssen Biotech

FORMA Therapeutics describes HDAC inhibitors

Immune Therapeutics initiates Malawi study of LDN for prevention of cervical cancer

FDA grants breakthrough status to Stemline's SL-401

Cyon Therapeutics licenses Novartis' anti-PCSK9 antibody LGT-209

Temple University discovers novel 5-HT7 antagonists to treat inflammatory bowel disease

Pfizer to acquire AstraZeneca's small molecule anti-infectives business

FDA accepts Clovis' NDA for rucaparib

GlaxoSmithKline and Astex present a novel potent and reversible inhibitor of PAF acetylhydrolase

Biocardia merges with Tiger X Medical, forms new entity

AiCuris Anti-infective Cures' pritelivir achieves primary endpoint in phase I trial

Nanoantibiotics changes name to Biovie

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...